Liraglutide seems effective in obesity, says FDA reviewer - PMLiVE
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity | Fierce Pharma
NOVO NORDISK GLP-1 PRESENTATION DESIGN on Behance
FDA Approves Novo Nordisk's Saxenda as a Treatment for Chronic Weight Management
Type 2 Diabetes and the Role of GLP-1 | Diabetes Education for Patients | novoMEDLINK™
GLP-1 diabetes drugs are being released one after another
Novo Nordisk doesn't feel threatened by GLP-1 rival Lilly
GLP-1 receptor agonist for chronic weight management - Clinical Advisor
Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its way | Fierce Pharma
Novo Nordisk's Ozempic is quick out of the blocks, chasing Lilly's Trulicity - PMLiVE
First Oral GLP-1 Receptor Agonist Approved for Type 2 Diabetes - MPR
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers - Nørgaard - 2022 - Alzheimer's & Dementia: Translational
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
Looking for Ozempic? Doctors are prescribing these diabetic alternatives for now | Connecticut Public
Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article - KBR
Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company | Medgadget
FDA approves Novo Nordisk's GLP-1 drug Rybelsus for first-line type 2 diabetes treatment
The 411 on a GLP-1“ auf Apple Podcasts
